Short answer
Korro Bio, Inc. (KRRO) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $0 (down 100.0% year over year) with net income of −$19M.
Q2 2026 key financials · XBRL
- Revenue
- $0
- −100.0% YoY
- Net income
- −$19M
- +26.6% YoY · +3.6% QoQ
- EPS (diluted)
- −$0.95
- +65.5% YoY · +43.8% QoQ
Source: XBRL data from the Korro Bio, Inc. (KRRO) Q2 2026 10-Q on SEC EDGAR. USD.
Korro Bio, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- KRRO-110 REWRITE trial failure triggered AATD program transition from LNP delivery to KRRO-111’s GalNAc-conjugated delivery
- KRRO-121 remains preclinical, with first-in-human regulatory filing anticipated in the second half of 2026
- GalNAc-conjugated REO delivery lacks FDA-approved precedent, creating efficacy risk across KRRO-121 and KRRO-111
- Evolving tariffs since April 2025 may increase supply-chain costs and disrupt clinical-site operations
- Cash, cash equivalents and marketable securities totaled $137.9 million, projected to fund operations into the second half of 2028
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Korro Bio, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.